Sun Yat-sen University Shenzhen Alumni Association Visits Sekbio: A Constructive Exchange on IVD Innovation, Quality, and Industry Collaboration

The Shenzhen Chapter of Sun Yat-sen University Alumni Association at Sekbio's facility, Shenzhen, May 2026.

In a visit that underscored the growing vitality of Shenzhen's life sciences and IVD ecosystem, the Shenzhen Chapter of the Sun Yat-sen University Alumni Association (中山大学深圳校友会) paid an official visit to Sekbio in May 2026. The delegation was warmly received by Sekbio's CEO and the company's senior management team, who hosted a comprehensive facility tour followed by a wide-ranging discussion on the in vitro diagnostics industry and opportunities for collaboration between the academic community and industry.

Facility Tour: From R&D Lab to Production Floor

Led by Sekbio's CEO, the visiting delegation was guided through the company's core operational areas, gaining firsthand insight into the full value chain of IVD antibody and recombinant protein manufacturing.

R&D Laboratories

The tour began in Sekbio's research and development laboratories, where the team showcased its work on monoclonal antibody development and recombinant protein expression. Sekbio's CHO and HEK293 mammalian expression platforms — capable of delivering proteins with yields up to 2.4 g/L — drew particular interest from the delegation, who noted the technical depth required to maintain consistent output quality across a portfolio of more than 1,000 proteins.

Cleanroom Manufacturing

The delegation then visited Sekbio's ISO-compliant cleanroom facilities, where antibody conjugation, labeling, and formulation processes are conducted under strictly controlled environmental conditions. The cleanroom design — segregated by process type and equipped with real-time environmental monitoring — reflects Sekbio's commitment to contamination control and batch-to-batch reproducibility, requirements that are non-negotiable in the IVD supply chain.

Production Line Quality Control

Particular attention was given to Sekbio's in-process and final quality control operations, including antibody titer measurement, specificity testing, cross-reactivity evaluation, and stability assessment. The delegation observed how quality data is systematically captured and reviewed against pre-defined acceptance criteria at every production stage — a practice embedded in Sekbio's broader quality management framework.

ISO 13485 Quality Management System

The final stop was a review of Sekbio's ISO 13485 quality management system implementation, which governs all activities from supplier qualification and document control through to customer feedback and CAPA (Corrective and Preventive Action) processes. Sekbio's quality team walked the delegation through how the QMS is operationalized in daily practice — not merely as a certification requirement, but as the structural backbone of the company's reliability promise to its 200+ IVD brand customers across 30+ countries.

Industry Dialogue: Challenges and Opportunities in IVD

Beyond the facility tour, the visit provided a valuable forum for candid discussion about the state of the global IVD industry. Both delegations exchanged perspectives on a range of themes:

• Market consolidation: The trend toward platform standardization and supplier rationalization is increasing the bar for raw material quality and supply chain reliability — areas where Sekbio's ISO 13485 certification and track record provide a meaningful competitive advantage.
• Regulatory evolution: Tightening IVD regulations in key markets — including the EU's IVDR transition and China's updated in vitro diagnostic regulations — are raising technical documentation requirements and placing new emphasis on the traceability of raw materials, including antibody pairs and recombinant antigens.
• Emerging biomarker opportunities: The delegation discussed how the expansion of point-of-care testing into new disease areas — including infectious disease surveillance, companion animal diagnostics, and chronic disease management — is generating demand for novel, high-performance immunoreagents that are not yet widely available in the market.
• The role of Chinese IVD companies globally: Chinese IVD manufacturers, once positioned primarily as low-cost suppliers, are increasingly recognized for their technical capabilities and quality standards. Sekbio's international customer base is evidence of this shift.

Alumni Association Support: Bridging Academia, Industry, and Capital

The Shenzhen Chapter of the Sun Yat-sen University Alumni Association expressed genuine care and encouragement for alumni-founded enterprises like Sekbio, and outlined several avenues through which the Alumni Association can facilitate resource integration and growth support:

Financing and Investment Connections

The Alumni Association has an established network of alumni investors, venture capital firms, and strategic partners with active interest in the life sciences and medical technology sectors. The association indicated its willingness to help connect Sekbio with suitable financing resources as the company continues to scale its manufacturing capacity and R&D capabilities.

University Research Collaboration

Sun Yat-sen University's research institutes — spanning biomedicine, chemistry, and public health — represent significant untapped potential for industry-academia co-development. The Alumni Association offered to facilitate introductions to relevant research groups for joint projects, technology transfer, or the co-development of new diagnostic biomarker targets. Such partnerships could accelerate Sekbio's pipeline of novel immunoreagents while providing academic teams with a direct commercialization pathway.

Government Project and Policy Resources

As a well-established alumni network with deep roots in Shenzhen's institutional landscape, the Alumni Association also offered to support Sekbio in identifying and applying for relevant government innovation programs, talent attraction policies, and industrial development grants — resources that can meaningfully reduce the cost of R&D investment and facility expansion for qualifying biotech companies.

CEO's Remarks: Gratitude, Commitment, and the Road Ahead

Sekbio's CEO extended sincere thanks to the Alumni Association for the time, insight, and commitment to supporting the growth of alumni enterprises. He reaffirmed Sekbio's dedication to its founding mission: building a trusted, globally competitive IVD raw material platform anchored in technical expertise and uncompromising quality standards.

Looking ahead, the CEO noted that Sekbio will continue to expand its product portfolio — including new antibody pairs for emerging diagnostic targets — while deepening its quality management infrastructure in line with evolving international regulatory requirements. The potential collaborations discussed during the visit, from academic co-development to investor introductions, will be actively explored in the coming months.

Frequently Asked Questions